XML 14 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Net revenues $ 3,910 $ 3,870 $ 7,892 $ 8,227
Cost of sales 2,037 2,107 4,141 4,402
Gross profit 1,873 1,763 3,750 3,826
Research and development expenses 248 225 501 446
Selling and marketing expenses 615 597 1,200 1,210
General and administrative expenses 242 264 532 567
Intangible assets impairments 195 120 274 768
Other assets impairments, restructuring and other items 28 381 165 502
Legal settlements and loss contingencies 6 13 110 (12)
Other income (43) (9) (48) (22)
Operating income (loss) 582 173 1,015 364
Financial expenses, net 274 223 564 448
Income (loss) before income taxes 308 (51) 451 (84)
Income taxes (benefit) 98 (104) 159 (163)
Share in (profits) losses of associated companies, net (11) 0 (14) 0
Net income (loss) 221 53 306 78
Net income (loss) attributable to non-controlling interests 14 (87) 21 (131)
Net income (loss) attributable to Teva $ 207 $ 140 $ 284 $ 209
Earnings (loss) per share attributable to ordinary shareholders:        
Basic $ 0.19 $ 0.13 $ 0.26 $ 0.19
Diluted $ 0.19 $ 0.13 $ 0.26 $ 0.19
Weighted average number of shares (in millions):        
Basic 1,103 1,096 1,101 1,095
Diluted 1,109 1,100 1,108 1,098